bluebird bio Newsroom

Investor Optimism Abounds Bluebird Bio, Inc. (NASDAQ:BLUE) But Growth Is Lacking

Simply Wall StDec 13 08:07 ET

Bluebird Bio Trading Halted, News Pending

TipRanksDec 12 19:55 ET

Express News | Trading Halt: Halted at 7:50:00 P.m. ET - Trading Halt: Halt News Pending

BenzingaDec 12 19:50 ET

Bluebird Bio To Carry Out 1-for-20 Reverse Stock Split On December 13th, 2024

Moomoo NewsDec 11 19:40 ET

Reported Sunday, Bluebird Bio Highlights 9-Year Data For LYFGENIA Gene Therapy: Sustained Benefits In Sickle Cell Disease Patients At ASH 2024

BenzingaDec 9 02:48 ET

Bluebird Bio Announced Long-Term Follow-Up Data Continue To Support Beti-Cel As Potentially Curative Gene Therapy For Β-Thalassemia Patients Who Require Regular Transfusions Through Achievement Of Durable Transfusion Independence And Normal Or...

BenzingaDec 7 15:30 ET

12 Health Care Stocks Moving In Thursday's Pre-Market Session

BenzingaDec 5 16:05 ET

Trending Stocks Today | PainReform Surges 67.16% Post-Market

Moomoo NewsDec 4 16:25 ET

Express News | Bluebird bio Announces 1-for-20 Reverse Stock Split

ReutersDec 4 16:05 ET

Bluebird Bio Announces 1-for-20 Reverse Stock Split

BusinesswireDec 4 16:05 ET

FDA-Approved Sickle Cell Therapies From Bluebird Bio And Vertex Join Medicaid Innovation Program

BenzingaDec 4 14:31 ET

Bluebird Bio Shares Are Trading Higher After the Company Announced It Joined the CMMI Cell and Gene Therapy Access Model and Will Offer Outcomes-based Agreements to Expand Medicaid Access to LYFGENIA Gene Therapy for Sickle Cell Disease.

BenzingaDec 4 14:23 ET

CMS Rolls Out New Payment Model for Vertex, Bluebird Gene Therapies

Seeking AlphaDec 4 12:40 ET

Bluebird Bio Participates in CMMI Cell and Gene Therapy Access Model

TipRanksDec 4 09:06 ET

Express News | CMS: Cell & Gene Therapy Access Model Launches in Jan 2025, States May Choose to Begin Participation Anytime Between Jan 2025 & Jan 2026

ReutersDec 4 08:47 ET

Express News | Bluebird bio Inc - States Can Opt in to Agreement Until February 28, 2025

ReutersDec 4 08:47 ET

Express News | Bluebird bio Confirms Participation in Center for Medicare and Medicaid Innovation (Cmmi) Cell and Gene Therapy Access Model

ReutersDec 4 08:47 ET

Express News | CMS: 2 Drug Manufacturers With FDA-Approved Gene Therapies for Sickle Cell Disease to Participate in Cell & Gene Therapy Access Model With CMS

ReutersDec 4 08:46 ET

Express News | Bluebird Bio Shares Are Trading Lower After the FDA Announced an Investigation Into a Serious Risk of Hematologic Malignancy Following Skysona

BenzingaNov 27 13:50 ET

FDA Investigating Safety Risks of Bluebird's Skysona

Seeking AlphaNov 27 13:49 ET